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Drug-drug interactions (DDI) occur when the effects 
of one drug are changed by the presence of another 
substance such as drugs, herbal products, and 
complementary medicines. Clinically significant DDIs 
are potentially life-threatening; therefore, it is essential 
to have a clear understanding and attention regarding 
the health care professionals towards DDIs and 
identify a proper management strategy (1).  
In late December 2019, early reports predicted 
the onset of a potential Coronavirus outbreak in China, 
given the estimate of a reproduction number for the 
2019 Novel Coronavirus (COVID-19, named by WHO 
on Feb 11, 2020). In a short period, the virus spread has 
occurred in many countries such as Italy and Iran (2). 
Currently, no effective antiviral treatment or vaccine is 
available for COVID-19 except for the old antimalaria 
medications, which are shown to have significant 
efficacy and safety against COVID-19 associated 
pneumonia in multicenter clinical trials conducted in 
China (3). Also, a group of Korean physicians with 
experience in treating SARS-CoV-2 infected patients 
have developed recommendations for the treatment of 
COVID-19. They have mentioned that treatment with 
lopinavir 400 mg daily; ritonavir 100 mg daily; 
chloroquine 1000 mg daily or hydroxychloroquine 400 
mg daily (where chloroquine is unavailable) should be 
considered for use in older patients or patients with 
underlying conditions and serious symptoms (4). 
In the setting of COVID-19 management, 
attention to probable DDIs between chloroquine (or 
hydroxychloroquine) and the other medications is 
necessary for healthcare providers. It seems that the 
most important DDIs are those which occur by the QT 
prolongation mechanism. Both chloroquine and 
hydroxychloroquine have been reported as causes of 
acquired QT interval prolongation. Prolongation of the 
QT interval can cause a potentially fatal polymorphic 
ventricular tachycardia called torsades de pointes 
(TdP) (5).  There is a list of medications involved in 
the induction of QT prolongation such as methadone, 
haloperidol, and ondansetron (5). It seems that 
attention to probable DDIs among medications 
induced QT prolongation and antimalarial medication 
using for the treatment of COVID-19 is important. The 
initial presentations or the chief complaints of some 
hospitalized patients with the COVID-19 infection are 
gastrointestinal symptoms such as nausea and 
vomiting (N/V). In this case, physicians may prescribe 
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ondansetron or metoclopramide; however, co-
administration of mentioned chloroquine or 
hydroxychloroquine may potentiate QT prolongation. 
It seems that it is better to prescribe medications such 
as diphenhydramine or dimenhydrinate for the 
management of N/V in these cases. On the other hand, 
anxiety and agitation are manifestations of COVID-19 
infections in some patients. Considering QT 
prolongation properties of several psychotropic 
medications, such as haloperidol and quetiapine, it is 
better to administer the other antianxiety medications 
such as diphenhydramine or chlordiazepoxide for the 
management of anxiety and agitation in these cases. As 
QT prolongation has been reported by methadone 
amongst opioids, administration of morphine or 
oxycodone is recommended for pain relief in COVID-
19 infected patients under treatment of either 
chloroquine or hydroxychloroquine. These examples 
show the importance of attention in drug selection and 
a prescription for treatment of COVID-19 infected who 
are treated by chloroquine or hydroxychloroquine. 
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